CPRX Q4 2020 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+3.0% YoY

Gross Profit

$26M84.3% margin

Operating Income

$9M27.8% margin

Net Income

$11M36.9% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$192M

Total Liabilities

$23M

Stockholders' Equity

$170M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$30M	+3.0%
Gross Profit	$26M	$26M	+1.6%
Operating Income	$9M	$8M	+7.6%
Net Income	$11M	$8M	+44.2%